Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

How does bone-marrow transplantation cure leukaemia?

R P Gale, R E Champlin

    Lancet (London, England)
    |July 7, 1984
    PubMed
    Summary

    Bone-marrow transplants from identical twins show higher relapse rates in acute myelogenous leukemia (AML) patients compared to HLA-identical siblings. This suggests the graft-versus-leukemia effect, not just chemotherapy, is crucial for successful AML treatment.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Long-term outcomes of Sleeping Beauty-generated CD19-specific CAR T-cell therapy for relapsed-refractory B-cell lymphomas.

    Blood·2020
    Same author

    HLA-mismatched bone marrow transplantation in severe aplastic anemia.

    Bone marrow transplantation·2017
    Same author

    Donor type, in addition to transplantation in chronic phase and myeloablative conditioning, influence transplant survival for patients with advanced chronic myeloid leukemia in the era of tyrosine kinase inhibitors.

    Leukemia·2017
    Same author

    Fludarabine with pharmacokinetically guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML/MDS patients.

    Bone marrow transplantation·2016
    Same author

    PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies.

    Leukemia·2016
    Same author

    Multi-center analysis of the effect of T-cell acute lymphoblastic leukemia subtype and minimal residual disease on allogeneic stem cell transplantation outcomes.

    Bone marrow transplantation·2016

    Area of Science:

    • Hematology
    • Immunology
    • Oncology

    Background:

    • Bone-marrow transplantation (BMT) is a standard treatment for acute myelogenous leukemia (AML).
    • The efficacy of BMT is often attributed to high-dose pre-transplant chemoradiotherapy.
    • The role of graft-versus-host disease (GVHD) in BMT success for AML is under investigation.

    Purpose of the Study:

    • To compare relapse rates in AML patients undergoing BMT from monozygotic twins versus HLA-identical siblings.
    • To investigate the contribution of the graft-versus-leukemia (GVL) effect to BMT success in AML.

    Main Methods:

    • Retrospective analysis of 31 BMTs from monozygotic twins and 339 BMTs from HLA-identical siblings.
    • Patients received similar chemoradiotherapy regimens prior to transplantation.
    • Actuarial relapse rates were calculated and compared between the two groups.

    Main Results:

    • The actuarial relapse rate was significantly higher in patients transplanted from monozygotic twins (59%) compared to HLA-identical siblings (18%).
    • The absence of GVHD in twin transplants may contribute to the increased relapse rate.
    • These findings suggest an immunotherapeutic component to BMT success in AML.

    Conclusions:

    • The success of allogeneic BMT in AML may depend substantially on the immunotherapeutic effect of the graft (GVL effect).
    • High-dose chemotherapy and radiation alone may not be sufficient for durable leukemia eradication.
    • Limited benefit may be expected from autotransplantation and intensified chemotherapy for AML if the GVL effect is critical.

    Related Experiment Videos